AKT3, but not AKT1 or AKT2, mediated the resistance to apoptosis in BRAF-targeted melanoma cells; promoted anchorage-independent growth in triple negative breast cancer; and controlled the VEGF-induced angiogenesis in ovarian cancer [34–36]. This evidence concerns the gene AKT3 and ovarian carcinoma.